MTPConnect Industry Fellowships Building Life Science Workforce Skills

Banner Image

17 August 2023

MTPConnect is pleased to announce that a further two highly skilled Australian medical science researchers have been selected to work with leading South Korean pharmaceutical company Yuhan Corporation and pioneering RNA therapeutics company Moderna in Melbourne, under the REDI Fellowship Program.

Dr Destiny Dalseno, a Research Fellow from WEHI will travel to South Korea to undertake a three-month project with Yuhan, focusing on drug development for solid tumours.

Dr Shayanti Mukherjee, a senior research scientist and lab head from The Hudson Institute of Medical Research will undertake a six-month project with Moderna’s Regional Research Centre for Respiratory Medicines & Tropical Diseases in Melbourne, involving R&D business operations.

MTPConnect CEO, Stuart Dignam, congratulated the sponsors, Yuhan and Moderna and the fellows, Dr Dalseno and Dr Mukherjee.

“The REDI Fellowships are improving engagement between researchers and industry and providing fellows with real-world innovation experiences within commercial industry settings,” Mr Dignam said.

"It’s great to see major multi-national companies like Yuhan and Moderna offering their expertise in science and biotechnology and connecting with Australia’s talented research community to drive global collaborations and connections.

“We’re also delighted to facilitate these fellowships that extend Australia’s research and commercial relationships with major biotech companies – they’re contributing to the development of a commercial-ready workforce in Australia’s life sciences sector,” Mr Dignam said.

Congratulations to:

Dr Destiny Dalseno, a Research Fellow from WEHI who will undertake a three-month project with Yuhan, one of South Korea's leading pharmaceutical companies, where she will work with the oncology drug development team. Dr Dalseno's project will focus on elucidating the mechanisms of action responsible for the efficacy of novel small molecules that have been rationally designed for the treatment of solid tumours.

Dr Shayanti Mukherjee, a senior research scientist and lab head from The Hudson Institute of Medical Research will undertake a six-month project with Moderna. Dr Mukherjee will be involved in the development of business operations of Moderna’s Regional Research Centre for Respiratory Medicines & Tropical Diseases in Melbourne, working closely with the Centre Director to develop operating frameworks.

REDI (Researcher Exchange and Development within Industry) is a Medical Research Future Fund initiative delivered by MTPConnect. The REDI Fellowship Program provides up to $250,000 per fellow, per annum to Australian, international and/or multinational companies to select a researcher, academic, clinician or technology transfer professional to collaborate on priority medical research projects involving discovery, translation and commercialisation.